| 19.0267 -1.653 (-7.99%) | 09-09 12:37 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 28.11 |
1-year : | 31.9 |
| Resists | First : | 24.07 |
Second : | 27.31 |
| Pivot price | 22.71 |
|||
| Supports | First : | 18.81 |
Second : | 15.65 |
| MAs | MA(5) : | 21.5 |
MA(20) : | 23.01 |
| MA(100) : | 24.96 |
MA(250) : | 21.9  |
|
| MACD | MACD : | -0.6 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 13.3 |
D(3) : | 23.1 |
| RSI | RSI(14): 29.6 |
|||
| 52-week | High : | 35 | Low : | 11.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SRZN ] has closed below the lower bollinger band by 19.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ SRZN ] is to continue within current trading range. Bollinger Bands are 10.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 23.07 - 23.19 | 23.19 - 23.28 |
| Low: | 20.38 - 20.5 | 20.5 - 20.59 |
| Close: | 20.52 - 20.69 | 20.69 - 20.84 |
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Tue, 08 Sep 2026
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema - Stock Titan
Wed, 02 Sep 2026
Surrozen to Present at Upcoming Healthcare Investor Conferences - markets.businessinsider.com
Fri, 14 Aug 2026
StemPoint Capital reports 5.0% Surrozen (SRZN) stake via shares and warrants - Stock Titan
Thu, 23 Jul 2026
Surrozen Inc. (SRZN) Slides 2.72% as Selling Pressure Intensifies Near Key Resistance - Unusual Put Volume - vinanet.vn
Tue, 21 Jul 2026
Surrozen Inc. (SRZN) Gains 3.75% as Shares Approach Key Resistance at $24.14 - RVOL Breakout - dars.gov.et
Tue, 21 Jul 2026
Surrozen Inc. (SRZN) Gains 3.75% as Shares Approach Key Resistance at $24.14 - Money Flow Index - vinanet.vn
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 104.8 (%) |
| Shares Short | 1,250 (K) |
| Shares Short P.Month | 971 (K) |
| EPS | -40.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -18.61 |
| Profit Margin | 0 % |
| Operating Margin | -207.4 % |
| Return on Assets (ttm) | -25.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 408.6 % |
| Gross Profit (p.s.) | -1.97 |
| Sales Per Share | 0.97 |
| EBITDA (p.s.) | -3.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -35 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -0.48 |
| PEG Ratio | 0 |
| Price to Book value | -1.02 |
| Price to Sales | 19.35 |
| Price to Cash Flow | -6.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|